GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytori Cell Research Institute Inc (TSE:3750) » Definitions » 3-Year Revenue Growth Rate

Cytori Cell Research Institute (TSE:3750) 3-Year Revenue Growth Rate : 11.00% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cytori Cell Research Institute 3-Year Revenue Growth Rate?

Cytori Cell Research Institute's Revenue per Share for the three months ended in Dec. 2023 was 円61.50.

During the past 12 months, Cytori Cell Research Institute's average Revenue per Share Growth Rate was -2.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 11.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -13.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Cytori Cell Research Institute was 30.20% per year. The lowest was -52.70% per year. And the median was -19.20% per year.


Competitive Comparison of Cytori Cell Research Institute's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Cytori Cell Research Institute's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytori Cell Research Institute's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytori Cell Research Institute's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cytori Cell Research Institute's 3-Year Revenue Growth Rate falls into.



Cytori Cell Research Institute 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Cytori Cell Research Institute  (TSE:3750) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Cytori Cell Research Institute 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cytori Cell Research Institute's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytori Cell Research Institute (TSE:3750) Business Description

Traded in Other Exchanges
N/A
Address
1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
Cytori Cell Research Institute Inc developing a new clinical approach to cell therapy to provide better medical care to patients by providing medical care that responds to unmet medical needs based on innovative regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.

Cytori Cell Research Institute (TSE:3750) Headlines

No Headlines